BDMD
Price
$0.09Alerts
Change
-$0.01 (-10.00%)
Updated
Nov 20 closing price
Capitalization
2.82M
Intraday BUY SELL Signals
CERS
Price
$1.85Alerts
Change
-$0.05 (-2.63%)
Updated
Nov 20 closing price
Capitalization
407.08M
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BDMD vs CERS

BDMD vs CERS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BDMD vs. CERS commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDMD is a Hold and CERS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BDMD with price predictions
Nov 20, 2026

BDMD in upward trend: price may jump up because it broke its lower Bollinger Band on October 19, 2026

BDMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 31 cases where BDMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BDMD's RSI Oscillator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on BDMD as a result. In 32 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.

The Moving Average Convergence Divergence (MACD) for BDMD just turned positive on November 11, 2026. Looking at past instances where BDMD's MACD turned positive, the stock continued to rise in 20 of 46 cases over the following month. The odds of a continued upward trend are 43%.

Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDMD advanced for three days, in 70 of 120 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for BDMD entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.081) is normal, around the industry mean (4.142). P/E Ratio (-0.159) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.371) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. BDMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CERS with price predictions
Nov 20, 2026

CERS's RSI Indicator ascending out of oversold territory

The RSI Oscillator for CERS moved out of oversold territory on November 11, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 167 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

CERS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CERS as a result. In 86 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for CERS turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

The 50-day moving average for CERS moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for CERS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.813) is normal, around the industry mean (4.142). P/E Ratio (-67.333) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. CERS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CERS: Fundamental Ratings
CERS
OUTLOOK RATING
1..100
77
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BDMDCERS
RSI
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
44%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
43%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 10 days ago
58%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
84%
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (BDMD: $0.09 vs. CERS: $1.85)
Brand notoriety: BDMD and CERS are both not notable
Both companies represent the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: BDMD: 14% vs. CERS: 155%
Market capitalization -- BDMD: $2.82M vs. CERS: $407.08M
BDMD [@Medical/Nursing Services] is valued at $2.82M. CERS’s [@Medical/Nursing Services] market capitalization is $407.08M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BDMD’s FA Score shows that 0 FA rating(s) are green while CERS’s FA Score has 2 green FA rating(s).

  • BDMD’s FA Score: 0 green, 5 red.
  • CERS’s FA Score: 2 green, 3 red.
According to our system of comparison, CERS is a better buy in the long-term than BDMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BDMD’s TA Score shows that 5 TA indicator(s) are bullish while CERS’s TA Score has 4 bullish TA indicator(s).

  • BDMD’s TA Score: 5 bullish, 2 bearish.
  • CERS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BDMD is a better buy in the short-term than CERS.

Price Growth

BDMD (@Medical/Nursing Services) experienced а -0.88% price change this week, while CERS (@Medical/Nursing Services) price change was -6.80% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -11.44%. For the same industry, the average monthly price growth was -15.18%, and the average quarterly price growth was -18.29%.

Reported Earning Dates

CERS is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Medical/Nursing Services (-11.44% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BDMD and

Correlation & Price change

A.I.dvisor tells us that BDMD and IRTC have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BDMD and IRTC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BDMD
1D Price
Change %
BDMD100%
-12.91%
IRTC - BDMD
27%
Poorly correlated
+0.51%
INFU - BDMD
22%
Poorly correlated
+2.06%
ECOR - BDMD
21%
Poorly correlated
-8.87%
CERS - BDMD
21%
Poorly correlated
-2.63%
LFWD - BDMD
20%
Poorly correlated
-5.46%
More

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-2.63%
ICUI - CERS
46%
Loosely correlated
-1.84%
UTMD - CERS
45%
Loosely correlated
-2.07%
RVTY - CERS
44%
Loosely correlated
-4.20%
ATRC - CERS
43%
Loosely correlated
+2.37%
DHR - CERS
43%
Loosely correlated
-3.16%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
STRAX.X0.007273-0.000152
-2.04%
Xertra cryptocurrency
MIR.X0.000537-0.000018
-3.28%
Mirror Protocol cryptocurrency
AMP.X0.000485-0.000020
-3.95%
Amp cryptocurrency
STX.X0.244612-0.018358
-6.98%
Stacks cryptocurrency
DNT.X0.005069-0.000597
-10.53%
district0x cryptocurrency